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Tbjective: We sought to examine the comparative improvement in health status after
rimary mitral valve repair versus replacement in patients with mitral valve regur-
itation in a longitudinal setting.
ethods: We prospectively followed 267 patients with mitral valve regurgitation
ho underwent primary mitral valve repair (n  163) and replacement (n 
04) between January 2002 and January 2005. Health status was evaluated at
aseline and 1, 3, and 12 months after surgery with the validated short-form 36
nd analyzed using generalized estimating equations with adjustment for pro-
ensity scores.
esults: Compared with patients undergoing mitral valve replacement, patients
equiring valve repair were younger and more likely to be male. The probability of
ostsurgical readmission because of cardiac events was low and similar between the
wo treatment groups. New York Heart Association functional class was signifi-
antly improved after both procedures, with better improvement achieved by mitral
alve repair (P  .01). For both treatment groups, scores for most of the short-form
6 domains were depressed at 1 month; however, after 3- and 12-month lags,
ramatic improvements were achieved in most of the domains. Adjusted changes in
he physical component score were similar between the two arms at each follow-up.
or the mental component score, patients who underwent repair showed significant
mprovements compared with patients who underwent replacement at both 3 months
difference: 4.84 points, P  .005) and 12 months (difference: 5.92 points, P 
001).
onclusions: Our study suggests that after mitral valve surgery, there is significant
mprovement in New York Heart Association functional class and health status,
specially in patients undergoing mitral valve repair.
itral regurgitation (MR) (acute or chronic) affects approximately 5 in
10,000 people.1 Although the numbers are not as overwhelming as are
those related to coronary artery bypass graft surgery, this is still a
ubstantial societal burden. Traditionally, operative procedures in mitral valve (MV)
urgery consisted mainly of valve replacement with tissue bioprosthetic or mechan-
cal valves. More recently, valve repair has become a generally accepted alternative
o replacement for surgical treatment of MR.2,3 Patients undergoing MV repair may
otentially have reduced incidence of thromboembolism and endocarditis, as well as
educed anticoagulation requirements, compared with those undergoing MV re-
lacement. Furthermore, MV repair may lead to greater functional durability than
an be achieved with bioprosthetic or mechanical valves, ultimately leading to
mproved long-term results. Preservation of the intrinsic mitral apparatus allows for
mprovement of postoperative ventricular function, which may reduce the long-term
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1257
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A
CDecurrence of symptoms and postoperative MR for patients
ndergoing MV repair as opposed to replacement.4,5
Outcomes assessment in MV surgery has traditionally
ocused on perioperative mortality and morbidity, or long-
erm survival.6,7 However, patients who are to undergo MV
urgery are typically interested in their postsurgical health
tatus, including symptoms, functionality, and quality of
ife. Furthermore, functional status and quality of life have
ncreasingly been considered as important patient-related
utcome measures of the efficacy of surgical treatment,
hich can be used to help patients for decision making
egarding choice of therapy. However, to date there are
imited data on health status (symptom burden, functional
tatus, and quality of life) post-MV surgery, an important
utcome of therapeutic interventions for patients with car-
iac valve disease.8,9
The Outcomes Assessment of Mitral Valve Replacement
nd Repair study is a multicenter, prospective, observational
egistry assessing and comparing a spectrum of outcomes
fter replacement and repair in patients with MR, with a
ocus on health status. The purpose of the present evaluation
s to prospectively examine the comparative effects of MV
epair and replacement on recovery from surgery, with a
ocus on postoperative quality of life and health status.
aterials and Methods
atient Population
rom January 2002 to January 2005, a total of 274 patients with
R (repair: 167; replacement: 107) admitted for their first MV
urgery were enrolled at Emory University, Mid-America Heart
nstitute, Yale University, and Toronto General Hospital. Among
hese 274 patients, 7 (4 with repair; 3 with replacement) died
uring follow-up and were excluded from the health status anal-
sis. A total of 171 patients completed all assessments at baseline
nd 1, 3, and 12 months of follow-up.
Potential patients for the study were identified through daily
creening of operations at the participating institutes. All patients
ere screened for contraindications to transesophageal echocardi-
graphy before surgery. Patients were excluded if they had previ-
us MV surgery, required concomitant aortic valve surgery, or
ere unable to consent because of a language barrier or being too
ick, or died before consenting to participate in the study. The
nstitutional review board at each site approved the study, and all
Abbreviations and Acronyms
MCS mental component score
MR mitral regurgitation
MV mitral valve
NYHA New York Heart Association
PCS  physical component score
SF-36  short-form health survey [36 items]atients provided written informed consent. s
258 The Journal of Thoracic and Cardiovascular Surgery ● Maata Collection
efore surgery, clinical assessment and health-related quality of
ife were evaluated with a set of questionnaires including recent
ardiac events/procedures, medications, and health status. Follow-up
as done through direct communication (telephone or letter) at 1,
, and 12 months after surgery to obtain recovery information
ncluding postsurgery cardiac events, death, and stroke. Health
tatus was also assessed at each postoperative time interval using
he same instruments as at baseline. Additional information, in-
luding baseline demographic and clinical data, was obtained from
he Society of Thoracic Surgeons Database or an equivalent clin-
cal database at each site.
ealth Status Measurement
ealth status assessments were evaluated with the Medical Out-
omes Trust Short-Form 36-item Health Survey (SF-36).10 SF-36
s a general-purpose questionnaire that has been used in multiple
tudies and offers the broadest review of quality of life. This
omprehensive short-form assesses 8 dimensions of health: phys-
cal function, role limitation attributable to physical problems,
odily pain, general health perceptions, vitality (energy and fa-
igue), social function due to physical or emotional problems, role
imitation due to emotional problems, and mental health. The
esponses to each of these questions were summed and trans-
ormed to 8 individual scores, ranging from 0 to 100 for each
omain, with higher scores indicating better functioning. These
ndividual scores can be combined into a summary physical com-
onent score (PCS) and mental component score (MCS). Validity,
eliability, and typical response rates of all SF-36 domains as
uantitative measures of clinical symptoms and quality of life were
ndependently established.11
tatistical Analysis
emographic and clinical characteristics at baseline and outcomes
easures at each follow-up were compared between patients un-
ergoing MV repair and patients undergoing replacement. Contin-
ous variables (age and the average time between baseline and
ollow-up evaluations) were compared with the Wilcoxon rank-
um test. Categoric variables were compared using the chi-square
r Fisher exact test.
Time to event outcomes, such as death and rehospitalization
ue to cardiac events (eg, cardiac arrhythmia, heart failure, addi-
ional MV surgery), were assessed by Cox proportional hazards
egression analysis after adjusting for key preoperative variables,
amely, baseline SF-36 scores, surgical type, demographic factors
age as a continuous variable, gender), and clinical characteristics,
ncluding history of hypertension, diabetes, myocardial infarction,
anadian Cardiovascular Society angina class, and New York
eart Association (NYHA) functional class. Proportionality as-
umption was assessed.
ropensity Score
V repair and replacement are not in equipoise, and most patients
ill undergo MV repair if possible. To reduce treatment selection
ias and determine the influence of type of MV surgery on out-
omes, a propensity score was developed using logistic regression
ccounting for baseline characteristics, recruiting sites, and health
tatus covariates for each observation.12 The actual propensity
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CDcore (between 0 and 1) is the estimated probability that an
ndividual receives the treatment of interest. The propensity score
as adjusted for in a series of analyses allowing a comparison of
V repair and replacement more comparable to a nonrandomized
tudy.
issing Data
ata may have been missing because the interview was not ad-
inistered or forms were not filled out completely at each time
oint (reflected by varying degrees of missing data across the
omains) or because patients died before the follow-up visit. To
upplement complete case analysis and assess any potential impact
f missing information on the analysis, we performed multiple
mputation by a Monte Carlo Markov chain approach13 to impute
issing SF-36 scores for surviving patients in the 8 domains at the
time points. Covariates used in multiple imputation included
reatment assignment, demographic factors, clinical characteris-
ics, and all SF-36 scores at the 4 time points.
The generalized estimating equations approach14 was used to
ompare SF-36 scores at each of the 4 time points between the 2
reatment arms, with or without adjustment for the propensity
core. Changes in SF-36 scores from baseline at 1, 3, and 12
onths were also compared using the same method. The propen-
ity score was added to the multivariate models as a covariate term,
n addition to treatment assignment and visit sequence (1, 3, and 12
onths). Interaction terms among treatment assignment, visit, and
uartile of the propensity score were examined.
All tests of statistical significance were 2-tailed. Statistical
nalyses were performed with the Statistical Analysis System,
ersion 9.1 (SAS Institute Inc, Cary, NC), and S-plus, version 7
Mathsoft Inc, Seattle, Wash).
ole of the Funding Source
he sponsor of the study had no role in the study design, data
ollection, data analysis, data interpretation, or writing of the
eport. The writing committee had final responsibility for the
ABLE 1. Comparison of baseline demographic and clinic
Patients with complete da
haracteristics
Mitral repair
(n  108)
Mitral replac
(n  63
ge (y, mean  SD) 59.4 12.4 63.0 11.
ale (n, %) 66 (61.7) 26 (41
ypertension (n, %) 43 (44.3) 33 (54
iabetes (n, %) 8 (8.3) 7 (11
revious MI (n, %) 6 (6.2) 7 (11
HF III/IV (n, %) 34 (36.2) 25 (41
ngina III/IV (n, %) 10 (9.4) 8 (12
reoperative LVD 44.8 11.1 (86) 42.4 12.
reoperative EF  55% (n, %) 52/93 (55.9) 21/46 (45
ostoperative EF  55% (n, %) 51/91 (56.0) 21/46 (45
schemic MR 9/85 (10.6) 3/40 (7.
HF, Congestive heart failure; MI, myocardial infarction; LVD, left ventri
eviation.ecision to submit for publication. t
The Journal of Thoracicesults
aseline Characteristics
he demographic and clinical characteristics for patients
ith complete evaluation at each follow-up time point and
he whole study population are shown in Table 1. For both
atient populations, patients in the MV replacement group
ere older than those in the MV repair group. Women were
ore likely than men to have MV replacement. In addition,
ore women had class III/IV congestive heart failure at
he time of surgery (52.2% vs 28.6%, P  .0001). For the
verall population, there was a tendency for patients in the
V replacement group to have higher rates of history of
yocardial infarction (P  .06) and class III/IV angina
P  .08). The proportion of patients with history of hy-
ertension, diabetes, and class III/IV congestive heart fail-
re was not significantly different between the 2 treatment
roups (all P  .2) for both patient populations. Baseline
haracteristics for the 171 patients who had completed
valuation during the study period were similar to those for
he 96 patients who did not complete follow-up, except that
atients who did not finish the study tended to be younger
57 years vs 61 years, P  .03).
linical Outcomes
here were no significant differences between the 2 treat-
ent groups in the length of time between the intervention
nd the interview dates at each of the 3 follow-up time
oints (1 month: 40.0 days for repair vs 40.8 days for
eplacement, P  .80; 3 months: 114.2 vs 122.7, P  .25;
2 months: 378.9 vs 381.2, P  .74).
There was significant improvement in the NYHA func-
ional class from baseline at each of the follow-up time
oints for both treatment groups. The percentages of pa-
aracteristics
 171) The whole population (n  267)
t
P value
Mitral repair
(n  163)
Mitral replacement
(n  104) P value
.059 58.1 12.2 61.6 12.9 .014
.010 110 (67.5) 44 (42.1) .0001
.23 74 (45.4) 50 (48.1) .67
.50 17 (10.4) 12 (11.5) .78
.24 12 (7.4) 15 (14.4) .06
.55 58 (35.6) 45 (43.3) .21
.49 15 (9.2) 17 (16.4) .08
.29 46.2 10.9 (112) 43.7 11.9 (53) .19
.23 66/122 (54.1) 31/70 (44.3) .20
.08 67/121 (55.4) 31/70 (44.3) .11
.59 11/111 (9.9) 5/63 (7.9) .90
dimension; EF, ejection fraction; MR, mitral regurgitation; SD, standardal ch
ta (n
emen
)
4
.3)
.1)
.5)
.5)
.0)
.7)
4 (38)
.7)
.7)
5)
cularients in class III/IV were significantly lower for the MV
and Cardiovascular Surgery ● Volume 133, Number 5 1259
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A
CDepair group than for the replacement group at 3 and 12
onths (Figure 1).
During follow-up, readmissions for cardiac events were
ow and there was no significant difference between the 2
reatment groups (6.6% for repair and 11.9% for replace-
ent, P  .28). The most common reason for readmission
as cardiac arrhythmia (2.2% for repair and 4.8% for re-
lacement, P  .42). The proportions of readmission due to
ach of the cardiac events were similar between the 2
roups. Mortality was low, with 7 patients (repair: 4; re-
lacement: 3, P  .88) dying during follow-up.
hanges in SF-36 Scores
Results from the complete data set (171 patients). At
aseline, the average, unadjusted scores for physical func-
ion (57.4 vs 41.0, P  .0006), role physical (43.1 vs 19.1,
 .0003), bodily pain (74.0 vs 61.2, P  .003), and PCS
39.9 vs 33.3, P  .003) were significantly higher for the
V repair group than for the replacement group, indicat-
ng that patients requiring MV repair had better physical
unction than did patients undergoing replacement. No
ignificant differences were found in other domains at
aseline.
After adjustment for the propensity scores, no differ-
nces were found at baseline between treatment groups in
ndividual domain and summary scores. At 1 month, pa-
ients in both groups worsened in most subscales while
mproving in general health perception and mental health,
ith more improvement obtained in the MV repair group
P  .05). From 3 months on, the effect of treatment on
ealth status was persistent over time, with patients under-
oing MV repair achieving better improvements in all do-
ains. The magnitudes of the differences in most domains
ere substantial and increased over time, corresponding to
igure 1. NYHA functional class III/IV at baseline and follow-up.
YHA, New York Heart Association; MV, mitral valve.etter improvements in performance in physical and social t
260 The Journal of Thoracic and Cardiovascular Surgery ● Mactivities, general satisfaction, and emotional state for MV
epair as opposed to replacement (Figure 2).
Estimated relative improvements from baseline and at 1,
, and 12 months in PCS and MCS for both treatment
roups based on the adjusted analysis are shown in Figure 3.
cores for PCS were depressed at 1 month for both groups,
ut they showed marked improvements at 3 and 12 months
fter surgery for both groups (P  .0001). The relative
mprovements between the 2 groups were not statistically
ignificant. At 1 month, MCS remained about the same for
he repair group, whereas it worsened for the replacement
roup; however, the change did not reach significance (P 
13). The repair group showed significant improvements
ompared with the replacement group and had significantly
etter changes from baseline in adjusted mean scores at both
he 3-month (difference: 4.84 points, P  .005) and 12-
onth (difference: 5.92 points, P  .001) time periods.
Results on incomplete data (267 patients). Average,
nadjusted, unimputed scores at baseline and 1, 3, and 12
onths from 267 patients were in general similar to those
rom the 171 patients with complete data (data not shown).
mputed, adjusted (controlling for the propensity score)
F-36 scores at each time point are, again, similar to those
rom the patients with complete data (data not shown).
owever, compared with the 171 patients who had com-
lete data for each of the 4 time points, the average relative
ains in MCS for MV repair versus replacement was
maller both at 3 months (difference: 3.20 points, P  .03)
nd at 12 months (difference: 3.34 points, P  .01).
ensitivity Analysis
dditional analyses were performed to examine the influ-
nce of missing data on the results. The primary analysis,
he results of which are described above, was based on the
ata sets for surviving patients with or without multiple
mputation. Two additional analyses were performed for
CS and MCS to examine the consequences of exclusion of
atients who died versus setting all SF-36 scores equal to 0
or those patients who died, with or without multiple impu-
ation. In these supplemental analyses, we assessed the
elative effects of MV repair versus replacement, using the
ame covariates listed earlier. Summaries are provided in
able 2. Estimates of the relative effects of MV repair
ersus replacement are presented with corresponding P val-
es. For PCS, the results were similar between data sets
ith or without imputation, both when excluding deaths and
hen setting scores to 0 for patients who died. For MCS,
esults based on imputed data with scores for deceased
atients set to 0 yielded the lowest or the most conservative
stimates of the effect of MV repair versus replacement.
evertheless, the relative benefits of MV repair remain
ighly significant for MCS regardless of the approach used
o treat 7 patients who died during follow-up.
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CDiscussion
he current study demonstrates that patients undergoing
V repair or replacement experienced significant recovery
year after intervention. Symptoms and NYHA functional
lass were greatly improved by surgery. The probability of
ostsurgery readmission because of cardiac events was low
nd similar between the 2 treatment groups.
The primary aim of surgical intervention for MR is to
mprove the overall functional capacity and health status of
atients. As a result, evidence of a meaningful benefit from
he patients’ perspective in the postintervention period is
ncreasingly recognized as an important consideration in the
ssessment of treatment strategies. The present analysis
ound that patients in both treatment groups acquired dra-
atic improvement in their personal health and emotional
tate at 3 and 12 months after surgery. They were able to
erform daily physical and/or social activities without phys-
cal limitations or emotional problems, particularly among
hose who underwent MV repair.
Currently, few data are available to describe health status
ecovery for patients undergoing MV surgery. Le Tourneau f
The Journal of Thoracicnd colleagues15 studied 24 patients undergoing MV repair
nd 16 patients requiring replacement. Despite an improve-
ent in NYHA functional class, exercise performance did
ot improve. In another study, Myken and colleagues16
oted no difference in coping capacity, social support, and
motional support between patients receiving mechanical or
ioprosthetic valve replacement. Quality of life was as-
essed at a single time. Goldsmith and colleagues17 evalu-
ted quality of life in 61 consecutive patients (40 underwent
epair, 21 underwent replacement) enrolled at a single cen-
er. Quality of life as measured by SF-36 was assessed
efore and at 3 months after surgery. Better improvements
ere achieved by patients who underwent MV repair. Over-
ll, the studies to date are mostly small, with insufficient
umbers of measurements to accurately predict quality of
ife outcomes of MV surgery.
MV repair may be more technically challenging to per-
orm than replacement, and the results may also be depen-
ent on surgeon volume. However, our results suggest that
atients undergoing MV repair have improved ventricular
Figure 2. Adjusted SF-36 scores
at baseline and 1, 3, and 12
months by treatment group in
patients with complete data. SF-
36, Short-form health survey [36
items]; MH, mental health; RE,
role-emotional; BP, bodily pain;
SF, social function; GH, general
health; PF, physical function; VT,
vitality; RP, role-physical.unction and better postoperative quality of life compared
and Cardiovascular Surgery ● Volume 133, Number 5 1261
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A
CDith patients undergoing replacement. The optimal timing
f MV surgery may therefore be earlier in the course of the
isease when repair is possible, before irreversible left ven-
ricular injury occurs.18 Indeed, this position was recently
dvocated by the American Heart Association/American
ollege of Cardiology consensus statement on the treatment
f vascular disease.19 Previous studies demonstrated lower
erioperative and long-term morbidity and mortality rates
or patients undergoing MV repair versus replacement sur-
ery.20 Our study reveals that patients’ perspective of health
tatus is also improved with MV repair, providing further
upport for the choice of MV repair over replacement.
eports from economic analysis also support the results of
he current study. For example, Barlow and colleagues21
oted a significantly lower mean cost with MV repair
$11,606 vs $14,469).
The present study has several possible limitations. First,
his was not a randomized trial; therefore, surgical proce-
ures were at the discretion of the individual surgeon, and
atient characteristics in the 2 treatment arms were intrin-
ically different. Propensity score adjustment was used to
educe treatment selection bias, allowing for a fairer com-
arison of the 2 techniques. Yet, without treatment random-
zation, any unmeasured sources of confounding cannot be
xcluded. Unfortunately, it would be difficult and poten-
ially unethical to recruit patients for a randomized trial
hen repair is possible.
A second potential limitation is the issue of missing data.
ecause willingness to participate was necessary to be
nrolled and followed up, our results could be affected by
esponse given the high rate of missing data. Explorations of
ny potential biases from missing patients were made, and
igure 3. Adjusted changes in PCS and MCS from baseline at 1,
, and 12 months by treatment group in patients with complete
ata. PCS, Physical component score; MCS, mental component
core; MV, mitral valve.o differences involving the rates of missing data and base- c
262 The Journal of Thoracic and Cardiovascular Surgery ● Maine characteristics were detected, except that patients who
id not finish follow-up were younger. Multiple imputation
nd sensitivity analyses were performed, and our main
onclusions about health status changes were materially
naffected.
A third consideration is that treatment assignment was
ot blinded, and the patients’ knowledge of the procedure
ight have influenced responses to the SF-36 questionnaire.
owever, the incorporation of patients’ perspectives of their
ealth is critical and congruent with the suggestion by the
nstitute of Medicine to make the health care system more
atient-centered.22
Finally, our study population may not include the sickest
atients because of the illness status and timing of surgery,
hich may make the generalizability imperfect. However,
n the basis of the patient characteristics and the proportion
f patients distributed between the treatment groups, we are
onfident that our conclusion can be applied to the current
ractice.
onclusions
his is the first multicenter longitudinal study following a
ohort of patients undergoing MV repair and replacement
ver time with repeated measures of health-related quality
f life. Our study demonstrated that there were significant
mprovements in NYHA functional class and health status 1
ear after MV surgery, with greater improvements among
atients undergoing MV repair. Continued efforts should be
irected toward understanding the mechanisms of improved
ealth status in patients undergoing MV repair. The results
f our study suggest that MV repair should be strongly
ABLE 2. Additional benefits of mitral valve repair versus
itral valve replacement from different models
Estimated additional benefits of MV
repair versus replacement (P value)
1 mo 3 mo 12 mo
hysical component score
Deaths excluded
No imputation 1.0 (.54) 0.6 (.74) 1.4 (.38)
Imputation 0.9 (.54) 0.4 (.80) 0.8 (.60)
Deaths as 0
No imputation 1.9 (.25) 0.9 (.65) 1.1 (.58)
Imputation 1.3 (.44) 0.5 (.74) 0.9 (.51)
ental component score
Deaths excluded
No imputation 3.6 (.04) 4.3 (.01) 4.0 (.01)
Imputation 2.3 (.12) 3.2 (.03) 3.3 (.01)
Deaths as 0
No imputation 2.2 (.24) 3.9 (.04) 3.5 (.07)
Imputation 1.6 (.28) 2.8 (.05) 2.7 (.05)
V, mitral valve.onsidered for MR whenever possible, and that the optimal
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Diming of surgery may be different in patients with repair-
ble pathology.
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